Reply  by Collins, Sean P. et al.
d
a
d
v
w
a
a
a
f
o
c
*
M
P
*
1
P
E
R
P
C
I
h
r
S
D
M
A
P
S
A
s
N
t
o
c
R
2491JACC Vol. 61, No. 24, 2013 Letters to the Editor
June 18, 2013:2487–93concept of using outpatient IV diuretic therapy for patients with
mild to moderate acute HF and have demonstrated the safety
and efficacy of this clinical approach (4). We fully support the
evelopment of a systematic approach to determine the most
ppropriate disposition of patients with varying degrees of acute
ecompensated HF or risk profiles (home vs. observation unit
s. hospital admission). We believe that an OIR capability as
ell should be incorporated into such an approach. The costs
ssociated with treating patients with fluid overload due to
cute HF in this manner are considerably lower than traditional
pproaches without jeopardizing safety (2). We encourage
urther studies that can clearly assess how the use of both
bservation units and OIRs can affect the cost-effectiveness of
are in the HF population.
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Reply
We appreciate the interest in our viewpoint and the opportunity to
reply to the letter by Dr. Ota and colleagues concerning our paper (1)
and an outpatient infusion clinic as an alternative to hospitalization in
low-risk acute heart failure (AHF) patients. All alternatives to hospital
admission in patients with AHF need to be explored. As Dr. Ota and
colleagues suggest, patients’ level of disease severity may be one of the
determinants of where and for what duration they may be managed.
Our preliminary work suggests those patients presenting to the
emergency department with a low-risk clinical profile who require
symptomatic therapy could be managed in an observation unit, safely
avoiding inpatient admission. This strategy has been suggested to be
safe and efficacious in observational studies, but should be tested in a
prospective, randomized fashion beforewidespread implementation (2,3).
Lazkani and Ota (4) suggest the use of an outpatient infusion
clinic for those low-risk patients who may not need 24 to 48 h of
management. They report that this transitional strategy has been
successful when managing AHF patients recently discharged fromthe hospital (4). Patients engage in self-care and contact the
transitional care provider when they experience signs or symptoms
of worsening heart failure. However, this approach also requires
a formal study of safety and efficacy. This approach is similar to
outpatient infusions with inotropic agents or nesiritide. Al-
though these approaches appeared safe and efficacious in
preliminary studies, once studied in a prospective, randomized
manner, they were found to not improve outcomes (5,6). In the
absence of rigorously acquired data, we cannot support an
outpatient infusion clinic for heart failure. The observation unit
strategy that we propose is markedly different and is based on
the safe triage of low-risk patients with an emphasis on the use
of evidence-based therapy in a careful randomized manner that
should definitively address the utility of our approach.
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